Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent
Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent
Sorry, the comment form is closed at this time.